Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation

Saved in:
Bibliographic Details
Published in:Leukemia research 2010-04, Vol.34 (4), p.e91-e93
Main Authors: Faber, Edgar, Mojzikova, Renata, Plachy, Radek, Rozmanova, Sarka, Stastny, Marek, Divoka, Martina, Jarosova, Marie, Indrak, Karel, Divoky, Vladimir
Format: Article
Language:English
Subjects:
Amino Acid Substitution - physiology
Antineoplastic Agents - therapeutic use
Cytogenetic Analysis
Dasatinib
Drug Resistance, Neoplasm - genetics
Hematology, Oncology and Palliative Medicine
Humans
Leucine - genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Male
Middle Aged
Phenylalanine - genetics
Protein Structure, Tertiary - genetics
Proto-Oncogene Proteins c-bcr - chemistry
Proto-Oncogene Proteins c-bcr - genetics
Pyrimidines - therapeutic use
Thiazoles - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2009.09.009